CytoSorbents Corp (NAS:CTSO)

$ 0.9366 0.0166 (1.8%) Market Cap: 51.47 Mil Enterprise Value: 72.59 Mil PE Ratio: 0 PB Ratio: 3.95 GF Score: 68/100

Q3 2024 Cytosorbents Corp Earnings Call Transcript
Nov 07, 2024

$0.898529 (-1.76%)

Earnings
Q2 2024 Cytosorbents Corp Earnings Call Transcript
Aug 13, 2024

$0.890569 (+0.43%)

Earnings
Q4 2023 Cytosorbents Corp Earnings Call Transcript
Mar 14, 2024

$0.965098 (-3.97%)

Earnings
Q3 2023 Cytosorbents Corp Earnings Call Transcript
Nov 09, 2023

$1.25 (-11.27%)

Earnings
Q2 2023 Cytosorbents Corp Earnings Call Transcript
Aug 01, 2023

$3.6 (+1.40%)

Earnings
Cytosorbents Corp at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Cytosorbents Corp Earnings Call Transcript
May 02, 2023

$2.36 (-4.44%)

Earnings
Q4 2022 Cytosorbents Corp Earnings Call Transcript
Mar 09, 2023

$3.56 (-4.02%)

Earnings
Q3 2022 Cytosorbents Corp Earnings Call Transcript
Nov 03, 2022

$1.94 (-3.94%)

Earnings
Q2 2022 Cytosorbents Corp Earnings Call Transcript
Aug 02, 2022

$2.33 (+3.08%)

Earnings
Cytosorbents Corp at UBS Global Healthcare Conference Transcript
May 23, 2022
Q1 2022 Cytosorbents Corp Earnings Call Transcript
May 03, 2022

$2.17 (-8.02%)

Earnings
Q4 2021 Cytosorbents Corp Earnings Call Transcript
Mar 08, 2022

$3.73 (+0.54%)

Earnings
Q3 2021 Cytosorbents Corp Earnings Call Transcript
Nov 04, 2021

$6.08 (-0.16%)

Earnings
Cytosorbents Corp Webinar on CytoSorb Therapy in COVID-19 Patients Transcript
Sep 16, 2021
Q2 2021 Cytosorbents Corp Earnings Call Transcript
Aug 03, 2021

$7.22 (-2.16%)

Earnings
Cytosorbents Corp Annual Shareholders Meeting Transcript
Jun 01, 2021
Cytosorbents Corp at UBS Global Healthcare Virtual Conference Transcript
May 26, 2021
Q1 2021 Cytosorbents Corp Earnings Call Transcript
May 04, 2021

$9.04 (-1.20%)

Earnings
Q4 2020 Cytosorbents Corp Earnings Call Transcript
Mar 09, 2021

$8.71 (+6.32%)

Earnings
Cytosorbents Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
Q3 2020 Cytosorbents Corp Earnings Call Transcript
Nov 04, 2020

$8.35 (-2.67%)

Earnings
Q2 2020 Cytosorbents Corp Earnings Call Transcript
Aug 04, 2020

$9.36 (-1.47%)

Earnings
Cytosorbents Corporation - Special Call Transcript
Jul 13, 2020
Cytosorbents Corp Annual Shareholders Meeting Transcript
Jun 02, 2020
Q1 2020 Cytosorbents Corp Earnings Call Transcript
May 05, 2020

$9.26 (-0.75%)

Earnings
Cytosorbents Corporation - Special Call Transcript
Apr 03, 2020
Full Year 2019 Cytosorbents Corp Earnings Call Transcript
Mar 05, 2020

$5.55 (-1.76%)

Earnings
Q3 2019 Cytosorbents Corp Earnings Call Transcript
Nov 05, 2019

$5.04 (+0.40%)

Earnings
Q2 2019 Cytosorbents Corp Earnings Call Transcript
Aug 06, 2019

$6.51 (-0.61%)

Earnings
Q1 2019 Cytosorbents Corp Earnings Call Transcript
May 07, 2019

$7.5 (-1.44%)

Earnings
Q4 2018 Cytosorbents Corp Earnings Call Transcript
Mar 07, 2019

$7.56 (-2.44%)

Earnings

Q2 2024 Cytosorbents Corp Earnings Call Transcript

Aug 13, 2024 / 08:30PM GMT

Release Date Price: $0.890569 (+0.43%)

Transcript 8-K10-Q

Operator

Ladies and gentlemen, good afternoon, and welcome to the CytoSorbents Second-Quarter 2024 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the company's request.

At this time, I'd like to turn the call over to our moderator, Eric Ribner. Please go ahead, Mr. Ribner.

Eric Ribner

LifeSci Advisors - Investor Relations

Thank you, and good afternoon. Welcome to CytoSorbents second quarter 2024 financial and operating results conference call. Joining me today from the company are Dr. Phil Chan, Chief Executive Officer; Vincent Capponi, President and Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe; and Christopher Cramer, Senior Vice President of Business Development.

Before I turn the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.